FR2832149B1 - Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique - Google Patents

Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique

Info

Publication number
FR2832149B1
FR2832149B1 FR0114542A FR0114542A FR2832149B1 FR 2832149 B1 FR2832149 B1 FR 2832149B1 FR 0114542 A FR0114542 A FR 0114542A FR 0114542 A FR0114542 A FR 0114542A FR 2832149 B1 FR2832149 B1 FR 2832149B1
Authority
FR
France
Prior art keywords
angiogenesis
pharmaceutical
cosmetic use
novel inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0114542A
Other languages
English (en)
Other versions
FR2832149A1 (fr
Inventor
Jacques Eustache
Jean Guy Boiteau
Celine Tarnus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0114542A priority Critical patent/FR2832149B1/fr
Priority to PCT/FR2002/003721 priority patent/WO2003040119A1/fr
Priority to JP2003542165A priority patent/JP2005519026A/ja
Priority to EP02795355A priority patent/EP1480964A1/fr
Priority to ARP020104286A priority patent/AR037341A1/es
Priority to US10/290,388 priority patent/US6803382B2/en
Publication of FR2832149A1 publication Critical patent/FR2832149A1/fr
Application granted granted Critical
Publication of FR2832149B1 publication Critical patent/FR2832149B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR0114542A 2001-11-09 2001-11-09 Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique Expired - Fee Related FR2832149B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0114542A FR2832149B1 (fr) 2001-11-09 2001-11-09 Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
PCT/FR2002/003721 WO2003040119A1 (fr) 2001-11-09 2002-10-29 Inhibiteurs de l'angiogenese
JP2003542165A JP2005519026A (ja) 2001-11-09 2002-10-29 血管新生阻害剤
EP02795355A EP1480964A1 (fr) 2001-11-09 2002-10-29 Inhibiteurs de l'angiogenese
ARP020104286A AR037341A1 (es) 2001-11-09 2002-11-08 Compuestos derivados de 1-oxa-espiro[2,5]octan-6-ol, metodo de sintesis de compuestos derivados de la fumagilina, composiciones farmaceuticas y cosmeticas que los comprenden, utilizacion de las composiciones farmaceuticas y utilizacion cosmetica de la composiciones cosmeticas
US10/290,388 US6803382B2 (en) 2001-11-09 2002-11-08 Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0114542A FR2832149B1 (fr) 2001-11-09 2001-11-09 Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique

Publications (2)

Publication Number Publication Date
FR2832149A1 FR2832149A1 (fr) 2003-05-16
FR2832149B1 true FR2832149B1 (fr) 2006-01-06

Family

ID=8869256

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0114542A Expired - Fee Related FR2832149B1 (fr) 2001-11-09 2001-11-09 Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique

Country Status (5)

Country Link
EP (1) EP1480964A1 (fr)
JP (1) JP2005519026A (fr)
AR (1) AR037341A1 (fr)
FR (1) FR2832149B1 (fr)
WO (1) WO2003040119A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872511B1 (fr) * 2004-06-30 2006-08-11 Galderma Res & Dev Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
US8299067B2 (en) * 2008-03-27 2012-10-30 Versitech Limited 5-demethoxyfumagillol and derivatives thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359036B1 (fr) * 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Dérivés de fumagillol
ES2053890T3 (es) * 1988-09-01 1994-08-01 Takeda Chemical Industries Ltd Agente inhibidor de la angiogenesis.
DE69001187T2 (de) * 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
WO1996026712A2 (fr) * 1995-02-28 1996-09-06 Handelman, Joseph, H. Emploi de suppresseurs d'angiogenese pour inhiber la pousse des poils
US6207704B1 (en) * 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
WO1999061432A1 (fr) * 1998-05-12 1999-12-02 Biochem Pharma Inc. Analogues de fumagillin et leur utilisation comme inhibiteurs de l'angiogenese

Also Published As

Publication number Publication date
JP2005519026A (ja) 2005-06-30
FR2832149A1 (fr) 2003-05-16
WO2003040119A1 (fr) 2003-05-15
WO2003040119A8 (fr) 2003-11-27
AR037341A1 (es) 2004-11-03
EP1480964A1 (fr) 2004-12-01

Similar Documents

Publication Publication Date Title
ATE275940T1 (de) Medizinische aerosolformulierungen von formoterol
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
FR12C0012I2 (fr) Combinaisons d'herbicides et de phytoprotecteurs
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
NO996433D0 (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
FI972657A (fi) Proteiinien ja peptidien aerosoliformuloinnit
NO995852D0 (no) Ny form av S-omeprazol
DE60024988D1 (de) Herstellung von therapeutischem mikroschaum
MA27034A1 (fr) Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
DE69836424D1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
HUP9902655A3 (en) Pharmaceutical composition of hedgehog proteins and use thereof
PT907364E (pt) Composicao farmaceutica de libertacao sustida
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
FR2834890B1 (fr) Composition pharmaceutique orodispersible d'agomelatine
EE200200271A (et) Ravimkombinatsioonid ning nende kasutamine
DE59708905D1 (de) Injektionsformulierungen von avermectinen und milbemycinen
ID26137A (id) Komposisi farmasi baru dari uridin trifosfat
FI965204A0 (fi) Bromelaiinin lääkekäyttö
FR2805461B1 (fr) Nouveaux agents de gommage cutane et nouvelles compositions cosmetiques
FR2832149B1 (fr) Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
FR2825102B1 (fr) Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
FR2824333B1 (fr) Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
FR2872511B1 (fr) Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
PT1140994E (pt) Proteinas da superficie externa, suas genes e sua utilizacao

Legal Events

Date Code Title Description
CA Change of address
ST Notification of lapse

Effective date: 20090731